OCUGEN, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
OCUGEN, INC. (OCGN) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$355.00 thousand for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-10.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-10
- OCUGEN, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was -$355.00K.
- OCUGEN, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was $747.00K.
- OCUGEN, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was $6.10M.
- OCUGEN, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$38.00K.
- OCUGEN, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$1.23M.
- OCUGEN, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$320.00K.
- OCUGEN, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$1.95M.
- OCUGEN, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$3.32M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2018-03-31 | -$355.00K 10-Q · filed 2018-05-10 | $392.00K derived: sum of 2 quarters · filed 2018-05-10 | $6.50M derived: sum of 3 quarters · filed 2018-05-10 | $6.46M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-12-31 | $747.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $6.85M derived: sum of 2 quarters · filed 2018-03-15 | $6.81M derived: sum of 3 quarters · filed 2018-03-15 | -$1.23M 10-K · filed 2018-03-15 |
| 2017-09-30 | $6.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $6.07M derived: sum of 2 quarters · filed 2017-11-09 | -$1.98M 10-Q · filed 2017-11-09 | -$1.98M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-06-30 | -$38.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | -$8.08M 10-Q · filed 2017-08-10 | -$8.08M derived: sum of 3 quarters · filed 2018-05-10 | -$8.09M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-03-31 | -$8.04M 10-Q · filed 2018-05-10 | -$8.05M derived: sum of 2 quarters · filed 2018-05-10 | -$8.05M derived: sum of 3 quarters · filed 2018-05-10 | -$8.33M derived: sum of 4 quarters · filed 2018-05-10 |
| 2016-12-31 | -$3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | -$6.00K derived: sum of 2 quarters · filed 2018-03-15 | -$288.00K derived: sum of 3 quarters · filed 2018-03-15 | -$320.00K 10-K · filed 2018-03-15 |
| 2016-09-30 | -$3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$285.00K derived: sum of 2 quarters · filed 2017-11-09 | -$317.00K 10-Q · filed 2017-11-09 | -$448.00K derived: sum of 4 quarters · filed 2017-11-09 |
| 2016-06-30 | -$282.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | -$314.00K 10-Q · filed 2017-08-10 | -$445.00K derived: sum of 3 quarters · filed 2017-08-10 | -$943.00K derived: sum of 4 quarters · filed 2017-08-10 |
| 2016-03-31 | -$32.00K 10-Q · filed 2017-05-11 | -$163.00K derived: sum of 2 quarters · filed 2017-05-11 | -$661.00K derived: sum of 3 quarters · filed 2017-05-11 | -$1.07M derived: sum of 4 quarters · filed 2017-05-11 |
| 2015-12-31 | -$131.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$629.00K derived: sum of 2 quarters · filed 2017-03-16 | -$1.03M derived: sum of 3 quarters · filed 2017-03-16 | -$1.95M 10-K · filed 2017-03-16 |
| 2015-09-30 | -$498.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | -$903.00K derived: sum of 2 quarters · filed 2016-11-10 | -$1.82M 10-Q · filed 2016-11-10 | -$3.56M derived: sum of 4 quarters · filed 2016-11-10 |
| 2015-06-30 | -$405.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | -$1.32M 10-Q · filed 2016-08-11 | -$3.06M derived: sum of 3 quarters · filed 2016-08-11 | -$4.45M derived: sum of 4 quarters · filed 2016-08-11 |
| 2015-03-31 | -$915.00K 10-Q · filed 2016-05-12 | -$2.66M derived: sum of 2 quarters · filed 2016-05-12 | -$4.04M derived: sum of 3 quarters · filed 2016-05-12 | -$4.12M derived: sum of 4 quarters · filed 2016-05-12 |
| 2014-12-31 | -$1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | -$3.13M derived: sum of 2 quarters · filed 2016-03-10 | -$3.20M derived: sum of 3 quarters · filed 2016-03-10 | -$3.32M 10-K · filed 2016-03-10 |
| 2014-09-30 | -$1.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | -$1.46M derived: sum of 2 quarters · filed 2015-11-12 | -$1.58M 10-Q · filed 2015-11-12 | |
| 2014-06-30 | -$73.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-12 | -$193.00K 10-Q · filed 2015-08-12 | ||
| 2014-03-31 | -$120.00K 10-Q · filed 2015-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |